Veterinary Medicines

CANIGEN CHPPI/L LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR DOGS

Authorised
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain Manhattan, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
  • Canine distemper virus, strain Lederle, Live
Download as PDF

Product identification

Medicine name:
CANIGEN CHPPI/L LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR DOGS
Active substance:
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain Manhattan, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
  • Canine distemper virus, strain Lederle, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine adenovirus 2, strain Manhattan, Live
    10000.00
    50% cell culture infectious dose
    /
    1.00
    unit(s)
  • Canine parainfluenza virus, strain Manhattan, Live
    100000.00
    50% cell culture infectious dose
    /
    1.00
    unit(s)
  • Canine parvovirus, strain Cornell 780916, Live
    100000.00
    50% cell culture infectious dose
    /
    1.00
    unit(s)
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
    4250.00
    enzyme-linked immunosorbent assay unit
    /
    1.00
    unit(s)
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
    4350.00
    enzyme-linked immunosorbent assay unit
    /
    1.00
    unit(s)
  • Canine distemper virus, strain Lederle, Live
    1000.00
    50% cell culture infectious dose
    /
    1.00
    unit(s)
Pharmaceutical form:
  • Lyophilisate and suspension for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Luxembourg
Package description:
  • 1 vial of lyophilisate and 1 vial of suspension
  • 100 vials of lyophilisate and 100 vials of suspension
  • 50 vials of lyophilisate and 50 vials of suspension
  • 25 vials of lyophilisate and 25 vials of suspension
  • 10 vials of lyophilisate and 10 vials of suspension

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • Ministry Of Health
Authorisation number:
  • V 859/17/06/1539
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0237/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."